Kornimate/medical-research-clean huggingface dataset:
tegoprazan and amoxicillin dual therapy

Conditions: H.Pylori Infection

Summary: dual therapy for helicobacter pylori refers to a treatment regimen that combines two agents: a potent acid suppressor (such as a proton pump inhibitor \[ppi\] or a potassium-competitive acid blocker \[pcab\]) and the antibiotic amoxicillin. this approach is increasingly recognized as a viable alternative to traditional triple or quadruple therapies, particularly in the context of rising resistance to other antibiotics such as clarithromycin and metronidazole. potent acid suppression increases the stability and activity of amoxicillin against h. pylori by maintaining a higher gastric ph, which is essential for optimal amoxicillin effect. high-dose dual therapy (e.g., amoxicillin 1,000 mg three times daily + standard dose of ppi three or four times daily for 14 days) has demonstrated eradication rates of 90%. in 2015, vonoprazan, a novel p-cab, was launched in japan and used as an alternative for ppis for eradicating h. pylori. dual therapy with vonoprazan and amoxicillin is particularly effective, with cure rates comparable to triple therapy and superior outcomes in clarithromycin-resistant infections. dual therapy is generally well tolerated, with adverse event rates similar to or lower than those seen with triple or quadruple regimens. in 2018, a new p-cab, tegoprazan, was developed in korea and approved for h. pylori eradication. however, there was no study of tegoprazan and amoxicillin dual therapy for the treatment of h. pylori.

the investigators aim to evaluate the h. pylori eradication success rate and treatment compliance of tegoprazan and amoxicillin dual therapy.

Eligibility criteria:
inclusion criteria: * gastroscopy can be performed * h. pylori test and pathological analysis can be performed exclusion criteria: * age \ 80 years * anemia (serum hemoglobin level \< 10 g/dl) * severe systemic disease * advanced chronic liver disease * use of certain medications, including proton pump inhibitors, h2- receptor antagonists, or antibiotics * history of h. pylori eradication * drug allergy to antibiotics * history of gastric surgery * recent history of upper gastrointestinal bleeding
short of pace - heart failure (shop-hf)

Conditions: Heart Failure With Preserved Ejection Fraction

Summary: this study is designed as a multicenter, prospective, controlled, randomized, two-arms, cross-over, two parallel cohorts, efficacy clinical research with ce-marked medical device . the crossover trial will be performed in a blind fashion, so each participant will be evaluated during both blinded pacing-on and pacing-off phases, each of which will last 3 months. the population includes patients with the diagnosis of stable hfpef according to criteria of the european society of cardiology and new york heart association (nyha) functional class ii-iii/iv, left ventricular hypertrophy with small ventricular volume, sinus rhythm with low basal heart rate and chronotropic incompetence (ci). all patients will undergo pacemaker implantation, and computer-generated randomization sequence previously designed will be used to allocate participants (in a 1:1 ratio) to receive: (a) programming of the pacemaker with pacing on followed by pacing off in two periods of 3 months; or (b) programming of the pacemaker with pacing off followed by pacing on in two periods of 3 months. the study will be conducted in three centers in spain. discounting the time due to staggered entry, the total duration of a patient's follow-up will be 7 months.


Eligibility criteria:
inclusion criteria: * stable symptomatic heart failure (nyha functional class ≥ii) during the last month. * diagnosis criteria of hfpef according to esc guidelines: 1. symptoms and signs of hf. 2. left ventricular ejection fraction ≥50% by simpson method. 3. probnp \>125 pg/ml in the last month. 4. at least one additional criterion: 1. relevant structural heart disease (left ventricular hypertrophy and/or left atrial enlargement); and/or 2. diastolic dysfunction. * left ventricular hypertrophy was defined as wall thickness \> 10 mm. * small ventricular volume was defined as indexed left ventricular end diastolic volume \< 45 ml/m2. * adults ≥18 years old. * previous admission for acute heart failure. * chronotropic incompetence assessed by cpet, defined as: \[(hrmax - hrrest)\]/\[(220 - age) - (hrrest)\] \< 0.62. * resting heart rate \< 65 bpm in sinus rhythm or 70 bmp in atrial fibrillation. exclusion criteria: * inability to perform a valid baseline exercise test. * significant primary pulmonary disease; including pulmonary arterial hypertension, chronic thromboembolic pulmonary disease or chronic obstructive pulmonary disease. * patient with prior history of left ventricular ejection fraction \<50%. * history of an acute coronary syndrome in the previous 12 months. * effort angina or signs of ischemia during cpet. * rer threshold at \<1.05 at the cpet. * significant primary moderate to severe valvular disease. * any other comorbidity with a life expectancy lower than 1 year. * heart rate at rest \> 75 lpm. * other pacemaker indication. * pregnant women. * baseline rhythm different from sinus rhythm or atrial fibrillation. * active treatment with beta-blockers, digitalis or non dihidropiridine calcium channel blockers.
safety and immunogenicity of gsk biological's candidate tuberculosis vaccine mtb72f/as02 in healthy ppd-negative adults.

Conditions: Tuberculosis (TB)

Summary: vaccination against tuberculosis (tb) /healthy ppd-negative adults aged 18 to 45 years.three doses of primary vaccination followed by a booster dose after completion of primary vaccination course. booster vaccination will be given only to subjects receiving the candidate tuberculosis vaccines and not to the subjects receiving active comparators or control.

the safety and immunogenicity of 2 antigen doses in ppd-negative adults will be evaluated. in addition, 2 active comparator groups of volunteers will receive the vaccine alone without an immunostimulant and 1 control group will receive the adjuvant (as02) alone to assess the true effect of the candidate tuberculosis vaccine (mtb72f/as02).

Eligibility criteria:
inclusion criteria: * written informed consent * healthy ppd-negative volunteers aged 18 to 45 years * no evidence of pulmonary pathology (i.e. acute or chronic pulmonary disease; past tb infection/disease) as confirmed by chest x-ray. * seronegative for hiv 1 and 2, hbsag, and hcv * clinically normal laboratory values for creatinine, alanine aminotransferase (alt), aspartate aminotransferase (ast), total bilirubin, complete blood count (cbc) and differential, haemoglobin, platelet count and urinalysis. * females : non pregnant, must use adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series. exclusion criteria: * chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose. * history of prior bacillus calmette-guérin (bcg) vaccination. * history of documented exposure to mycobacterium tuberculosis * history of prior vaccination with experimental mycobacterium tuberculosis vaccines or experimental products containing mpl or qs21. * any confirmed or suspected immunosuppressive or immunodeficient condition; or family history of congenital or hereditary immunodeficiency. * history of hypersensitivity to vaccines or vaccine components * history of any acute or chronic illness or medication that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine
the association between parent anxiety and sedation anesthesia doses in pediatric endoscopy

Conditions: Anxiety; Anesthesia

Summary: our study was planned as a prospective, single-center study between 20 january 2022 and 20 april 2022. all patients between the ages of 1-18 who will undergo upper or lower gastrointestinal endoscopy and their parents will be included in our study. all patients and parents whose family did not give consent to participate in the study will be excluded from the study. all patients will be seen by an anesthesiologist before the procedure and it will be stated that there is no harm in taking anesthesia. anesthesia consent form will be given by the family. study participation consent will be obtained from parents before starting the procedure. the patient's age, gender, height, weight, asa score, the procedure to be performed, the parent's educational status, occupation and income level will be recorded. children's anxiety will be evaluated with the "modified yale preoperative anxiety scale (mypas)" in the presence of their parents 15-30 minutes before the procedure. the agitation that occurs when the patient leaves the families for processing, with the "parental separation anxiety scale"; parental anxiety will be evaluated with the "stationary and trait anxiety scale" filled by families after the child is processed.


Eligibility criteria:
inclusion criteria: * all patients between the ages of 1-18 who will undergo upper or lower gastrointestinal endoscopy and their parents will be included in our study. exclusion criteria: * all patients and parents whose family did not give consent to participate in the study will be excluded from the study.
rct to evaluate social skills in children with autism using vr technology (socavr)

Conditions: Autism Spectrum Disorder; Social Communication

Summary: the goal of this randomized clinical trial is to compare and learn about virtual reality (vr) in children with autism/autistic children. the main question it aims to answer is: • does the floreo vr clinical product show clinical improvement in autism symptoms? participants will engage the vr product for twice a week for twelve weeks. they will be randomized to either the floreo clinical product or a vr control group experience. researchers will compare the two groups to see if there is an effect on learning specific skills and behaviors.

the purpose of this study is to find out if floreo's vr clinical program can help with autism symptoms such as social communication skills in autistic children. recent advances in vr technology offers a new way to improve these types of skills in children with autism in an immersive and controlled environment. questionnaires answered by adult caregivers will be used to assess the child's behaviors during the time of treatment. clinician observations will also be conducted as a part of this study.

Eligibility criteria:
inclusion criteria: * five to eighteen years old (inclusive) at the time of consent * legal guardian is able and willing to properly sign and date informed consent indicating that they have been informed about the study and able to complete all visits \[if age appropriate, an assent will also be administered to the participant to inform them of the study and give them an opportunity to proceed or decline\] * verified diagnosis of asd documented by a qualified clinician according to dsm-v criteria * receiving therapies at least two times per week in a clinic setting * participant is able to complete and pass the vr orientation screening exclusion criteria: * significant medical condition(s) \[examples listed below\] or other circumstances which, in the opinion of the treating clinician, would preclude compliance with the protocol, adequate cooperation in the study, or may prevent the participant from safely participating in the study: * uncontrolled neurological conditions such as epilepsy, migraine * current disorders affecting balance, such as vertigo * primary sensory impairment such as blindness or deafness * eye movement impairment, such as strabismus * participants are enrolled in another clinical study * participants known to be pregnant * participation in this study is not in the best interest of the child, at the discretion of the treating clinician and the primary investigator.

Keywords: virtual reality
evaluating negative pressure wound therapy in breast conserving surgery

Conditions: Breast Cancer; Seroma; Wound Complication

Summary: negative pressure wound therapy (npwt) could improve surgical outcomes and reduce complications like ssi, wound dehiscence and seroma in closed surgical wounds. to date, npwt was not evaluated in patients undergoing breast conserving surgery without direct reconstruction.therefore, the aim of this trial is to evaluate the feasibility of npwt after surgery and its effects on postoperative complications.

rationale: negative pressure wound therapy (npwt) could improve surgical outcomes and reduce complications like ssi, wound dehiscence and seroma in closed surgical wounds. complication rate after breast conserving surgery for breast cancer is 2-17%, surgical site infections (ssi) being the most common. to date, npwt was not evaluated in patients undergoing breast conserving surgery without direct reconstruction. therefore, in this trial, the aim is to evaluate the feasibility of npwt after breast conserving surgery and its effects on postoperative complications. objective and study parameters: primary objective is to compare surgical site complications in patients with and without npwt. secondary objective is to assess the number of re-interventions, unplanned visits and pain scores. study design: a prospective cohort of 150 patients will be compared to a retrospective cohort of 150 patients. study population: breast cancer patients undergoing breast conserving surgery with or without sentinel lymph node biopsy. intervention (if applicable): negative pressure wound therapy. nature and extent of the burden and risks associated with participation, benefit and group relatedness: when participating in this study, patients will need to pay at least one extra visit to the hospital, possibly two if this cannot be combined with the standard postoperative visits. in addition, patients will need to have a device with them for 14 days after surgery. this device is connected to the wound dressing. all wound dressings may cause irritation or an allergic reaction. this risk is not higher than when receiving standard wound dressing, but it is something to take into consideration. patients participating in this study may benefit from npwt regarding the postoperative complication rate.

Eligibility criteria:
inclusion criteria: * eighteen years or older. * female sex. * indication for breast conserving surgery, with or without sentinel lymph node biopsy. exclusion criteria: * undergoing mastectomy or modified radical mastectomy. * undergoing direct breast reconstruction. * patients with a pacemaker, intra cardiac defibrillator (icd) or other medical device in the proximity of the wound area, due to the magnet in the pico® device. * unable to comprehend implications and extent of the study and/or unable to sign for informed consent. * participation in another breast cancer surgery related clinical trial.
clinical trial of cinobufacini injection combined with oxaliplatin regimen on gastrointestine carcinoma

Conditions: Gastrointestinal Neoplasms

Summary: the clinical trail of cinobufacini injection combined with oxaliplatin regimen on gastrointestine carcinoma.this trail is randomized controled.patients are diagnosed gastrointestinal cancer based on pathology or cell biology.they are randomized into 2 groups:both groups receive oxaliplatin regimen.the treatment group receives cinobufotalin 20ml mixed with 5% glucose injection 500ml from the first day of chemotherapy until seven days in addition to the chemotherapy.the control group only receive the same chemotherapy with the treatment group.both group have the same adjuvant therapy.mainly to study of oxaliplatin into cinobufacini injection leads to the influence of the peripheral nerve toxicity.clinical evaluation includes neural electrophysiological test,chemotherapy drug toxicities,quality of life(qol),etc.blood biochemistry tests mainly include inflammatory cytokines,peroxidase reaction,immune cell number ratio and stress hormone,etc.


Eligibility criteria:
inclusion criteria: * age:18-70 * male and female * signed the informed consent form. * diagnosis:gastrointestinal cancer diagnosed by imaging,cell and pathology report. * eastern cooperative oncology group(ecog)o-2,life expectancy more than 3 months. * indication for chemotherapy,no contraindication. * first time chemotherapy or at least 6 months after last chemotherapy and radiotherapy. * at least 8 weeks after last biotherapy. * surgery:had not received transplantation surgery,at least 2 weeks after last major surgery. exclusion criteria: * chemotherapy is contraindicated. * have the primary disease can cause the neuropathy. * a history of other malignant tumor in recent 5 years. * less than 6 months after last chemotherapy or radiotherapy. * less than 8 weeks after last biotherapy. * cinobufotalin allergy. * had received transplantation surgery,less than 2 weeks after last major surgery. * other researchers think is not suitable for this clinical trail.
mhealth for patient self-management of opioid use disorder

Conditions: Opioid-use Disorder

Summary: twenty individuals diagnosed with opioid use disorder (oud) will be recruited to participate in a beta test to demonstrate feasibility of using an online tool to help them better self-manage their recovery.

participants will be enrolled in a 4-week single group pre-post evaluation. all participants will attend a two hour orientation to complete baseline assessments, learn how to access and use the software, and participate in a training session. study participants will be asked to complete assessments online at least three times per week, but no more than once daily. the software may still be accessed by participants as many times as desired to review advice and graphs. after the four week evaluation phase, participants will return for a two hour debriefing and completion of assessment surveys. this approach permits users to be adequately trained while also evaluating the software within their typical environment rather than in a lab setting.

Eligibility criteria:
inclusion criteria: 1. male or female outpatients 18 years of age or older; 2. opioid use disorder as assessed by mini 6.0; 3. currently stable in oud outpatient treatment for 4 weeks or longer; and 4. ability to access kios-oud via computer, smartphone, or tablet. exclusion criteria: 1. are unwilling or unable to comply with study requirements; 2. have a major untreated psychiatric illness (e.g., schizophrenia, bipolar disorder) or suicidality.
evaluation of safety and efficacy of pdp-716

Conditions: Open Angle Glaucoma; Ocular Hypertension

Summary: the study will be conducted to evaluate the efficacy and safety of topical administration of pdp-716 compared with brimonidine tartrate ophthalmic solution.


Eligibility criteria:
inclusion criteria: 1. be male or female, of 2 years of age or older 2. have open-angle glaucoma or ocular hypertension in both the eyes 3. be able and willing to follow study instructions and complete all required visits. exclusion criteria: 1. females who are pregnant/lactating. 2. have uncontrolled systemic disease which might interfere with the study 3. any known allergy or sensitivity to the study medications or their components 4. any other clinically relevant abnormality
spinal manipulative therapy for low back pain

Conditions: Low Back Pain

Summary: context: acute low back pain (lbp) is a common reason for consultations in primary care. reducing the pain in the first hours and days and restoring the functional capacity of the lumbar spine may result in a decrease in medical costs and earlier return to work. objective: to determine the impact of spinal manipulation on pain and analgesic use in acute low back pain.

design: randomised controlled parallel-group trial comparing standard care plus spinal manipulative therapy with standard care alone. intention-to-treat analysis. patients: outpatients with acute low back pain. setting: emergency department of bern university hospital and a primary care practice network.

Eligibility criteria:
inclusion criteria: 1. age between 20 and 55 years 2. duration of acute low back pain less than 4 weeks 3. informed consent exclusion criteria: 1. pregnancy 2. radicular origin of back pain (with irradiation) 3. cauda equine syndrome 4. neurologic deficit 5. epidural glucocorticoid injections in the preceding three months 6. previous low back surgery 7. severe osteoporosis 8. blood-coagulation disorder 9. allergy to planned rescue medications 10. suspicion of a specific cause of low back pain (fracture, tumor, infection, inflammatory disease of the spine, hiv-infection) in the patient's history or by physical examination 11. history or signs of severe dysfunction of the liver or kidney

Keywords: low back pain spinal manipulative therapy randomised controlled trial
efficacy of local food extracts at different storage times

Conditions: Food Allergy

Summary: local lyophylized food extracts are available useful in skin prick test and atopy patch test to confirm food allergy. however, the investigators want to know the duration that the investigators can keep the extracts for the usage in this purpose.

food allergy incidence increases world wide. the diagnosis mostly depends on history. skin prick test and atopic patch test are useful in finding the causative foods in some cases. the local food extracts have been shown to be at least as effective as commercial ones. from previous study the investigators keep the extract at 2-8 degree celsius for 1-3 months for the usage. the investigators want to evaluate the duration that the extracts are still useful in diagnosis food allergy

Eligibility criteria:
inclusion criteria: * positive skin prick test to one of the food (milk, egg, soy, wheat, seafood) exclusion criteria: * chronic diseases such as heart disease, liver, renal and severe sepsis * severe allergic symptoms such as anaphylaxis * extensive skin rashes * pregnancy

Keywords: food allergy skin prick test atopy patch test
clinical validation of suntech advantage mx with suntech neonate and children cuff line

Conditions: Hypertension

Summary: patients will be selected according to specific criteria. upon selection, patients with an existing intra-arterial line will have their blood pressure monitored with the suntech advantage mx module in addition to the reference data collected from intra-arterial line. data collected from the advantage mx module will be compared to the reference data from the intra-arterial line.


Eligibility criteria:
inclusion criteria: * at least 3 subjects shall be \< 1,000g in weight. * at least 3 subjects shall be 1,000g to 2,000g in weight. * at least 3 subjects shall be \>2,000g * at least 3 subjects shall be ≥ 29 days and \< 1 year of age. * at least 3 subjects shall be ≥ 1 year and \< 3 years of age. exclusion criteria: * subjects who study personnel determine invasive blood pressure measurements will be unreliable * patients found to have a-fib, irregular heart rhythm, dysrhythmias, bigeminy, trigeminy, and isolated premature ventricular beats (vpbs) during the enrollment process are to be ineligibile to participate in the study * patients who are prescribed anti-coagulation medication during the enrollment process or begin anti-coagulation medication after enrollment are ineligible to participate in the study. * exclusions can also occur post-data review based on exclusion criteria according to ansi/aami/iso 81060-2:2019